Why aren’t we doing better in asthma: Time for personalised medicine?

Primary Care Respiratory Medicine

Volumn 25, Issue , 2015, Pages

  Thomas, Mike ^a,b,c,d  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^c University Hospital Southampton NHS Foundation Trust   (United Kingdom)

^d NIHR Wessex Collaboration for Leadership and Research in Health Care   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID;

ANXIETY; ARTICLE; ASTHMA; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG DELIVERY DEVICE; FUNCTIONAL NEUROIMAGING; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; HYPERVENTILATION; INFLAMMATION; LUNG INJURY; MORTALITY; PERSONALIZED MEDICINE; PHENOTYPE; QUALITY OF LIFE; SELF CARE; TACHYPHYLAXIS; DISEASE COURSE; DOCTOR PATIENT RELATION; OUTCOME ASSESSMENT; PRACTICE GUIDELINE;

ASTHMA; DISEASE PROGRESSION; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PHYSICIAN-PATIENT RELATIONS; PRACTICE GUIDELINES AS TOPIC; PRECISION MEDICINE;

EID: 84924581170     PISSN: None     EISSN: 20551010     Source Type: Journal    
DOI: 10.1038/npjpcrm.2015.4     Document Type: Article

References (53)

1. Eder W, Ege MW, von Mutius E. The asthma epidemic. N Engl J Med 2006; 335: 2226–2235.
2. Tattersfield AE, Knox AJ, Britton JP, Hall IP. Asthma. Lancet 2002; 360: 1313–1322.
3. Martinez FD, Vercelli D. Asthma. Lancet 2013; 382: 1360–1372.
4. Masoli M, Fabian D, Holt S, Beasley R. Global Initiative for Asthma (GINA) Program The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59: 469–478.
5. Levy M, Andrews R, Buckingham R, Evans H, Francis C, Houston R et al. Why Asthma Still Kills: The National Review of Asthma Deaths (NRAD) Confidential Enquiry report. RCP: London, 2014. Available at https://www.rcplondon.ac.uk/sites/default/files/why-asthma-still-kills-full-report.pdf.
6. Demoly P, Gueron B, Annunziata K, Adamek L, Walters RD. Update on asthma control in five European countries: results of a 2008 survey. Eur Respir Rev 2010; 19: 150–157.
7. Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur Respir J 1996; 9: 636–642.
8. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009; 180: 59–99.
9. Department of Health, UK. An outcomes strategy for people with chronic obstructive pulmonary disease (COPD) and asthma 2011. Available at https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/216139/dh_128428.pdf (2011).
10. Anderson HR, Gupta R, Strachan DP, Limb ES. 50 Years of asthma: UK trends 1955-2004.Thorax 2007; 62: 85–90.
11. NHS. NHS Atlas of variation in healthcare for people with respiratory disease. Available at www.tightcare.nhs.uk/atlas/ (2012).
12. Haahtela T, Tuomisto LE, Pietinalho A, Klaukka T, Erhola M, Kaila M et al. A 10 year asthma programme in Finland: major change for the better. Thorax 2006; 61: 663–670.
13. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170: 836–844.
14. Enright P. The use and abuse of office spirometry. Prim Care Respir J 2008; 17: 238–242.
15. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000; 16: 802–807.
16. Thomas M, Turner S, Leather D, Price D. High dose inhaled corticosteroid use in childhood asthma: an observational study. Br J Gen Pract 2006; 56: 788–790.
17. Guthrie B, Payne K, Alderson P, McMurdo ME, Mercer SW. Adapting clinical guidelines to take account of multimorbidity. BMJ 2012; 345: e6341.
18. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343–373.
19. Haldar P, Pavord I, Shaw D, Berry M, Thomas M, Brightling C et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178: 218–224.
20. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008; 372: 1107–1119.
21. Heaney LG, Robinson DS. Severe asthma treatment: need for characterising patients. Lancet 2005; 365: 974–976.
22. Bousquet J, Addis A, Adcock I, Agache I, Agusti A, Alonso A et al. Integrated care pathways for airway diseases (AIRWAYS-ICPs). Eur Respir J 2014; 44: 304–323.
23. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343: 332–336.
24. Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax 2002; 57: 880–884.
25. Adams N, Bestall JM, Lasserson TJ, Jones PW. Inhaled fluticasone versus inhaled beclomethasone or inhaled budesonide for chronic asthma in adults and children. Cochrane Database Syst Rev (2): CD002310.
26. Horne R. Compliance, adherence, and concordance: implications for asthma treatment. Chest 2006; 130(1 Suppl): 65S–72S.
27. Williams LK, Pladevall M, Xi H, Peterson EL, Joseph C, Lafata JE et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol 2004; 114: 1288–1293.
28. Sears MR. Safety of long-acting beta-agonists: are new data really required? Chest 2009; 136: 604–607.
29. DeWeever A. Asthma patients must share responsibility. Pulse 2014; June:48. http://content.yudu.com/Library/A2vogl/PulseJune2014/resources/48.htm.
30. Gibson PG, Powell H, Wilson A, Abramson MJ, Haywood P, Bauman A et al. Selfmanagement education and regular practitioner review for adults with asthma. Cochrane Database Syst Rev 2003; CD001117.
31. Wilson SR, Strub P, Buist AS, Knowles SB, Lavori PW, Lapidus J et al. Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. Am J Respir Crit Care Med 2010; 181: 566–577.
32. Stoloff SW, Stempel DA, Meyer J, Stanford RH, Carranza Rosenzweig JR. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol 2004; 113: 245–251.
33. Gamble J, Stevenson M, Heaney LG. A study of a multi-level intervention to improve non-adherence in difficult to control asthma. Respir Med 2011; 105: 1308–1315.
34. Morrison D, Wyke S, Agur K, Cameron EJ, Docking RI, Mackenzie AM et al. Digital asthma self-management interventions: a systematic review. J Med Internet Res 2014; 16: e51.
35. Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J 2002; 19: 246–251.
36. Lenney J, Innes JA, Crompton GK. Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices. Respir Med 2000; 94: 496–500.
37. Virchow JC, Crompton GK, Dal Negro R, Pedersen S, Magnan A, Seidenberg J et al. Importance of inhaler devices in the management of airway disease. Respir Med 2008; 102: 10–19.
38. Teeter JG, Bleecker ER. Relationship between airway obstruction and respiratory symptoms in adult asthmatics. Chest 1998; 113: 272–277.
39. Juniper EF, Wisniewski ME, Cox FM, Emmett AH, Nielsen KE, O'Byrne PM. Relationship between quality of life and clinical status in asthma: a factor analysis. Eur Respir J 2004; 23: 287–291.
40. Rimington LD, Davies DH, Lowe D, Pearson MG. Relationship between anxiety, depression, and morbidity in adult asthma patients. Thorax 2001; 56: 266–271.
41. Thomas M, Bruton A, Moffat M, Cleland J. Asthma and psychological dysfunction. Prim Care Respir J 2011; 20: 250–256.
42. Spinhoven P, Peski-Oosterbaan AS, Van der Dooes AJ, Willelms NJ, Sterk PJ. Association of anxiety with perception of induced bronchoconstriction in patients with asthma. Thorax 1997; 52: 149–152.
43. Lavoie KL, Bacon SL, Barone S, Cartier A, Ditto B, Labrecque M. What is worse for asthma control and quality of life: depressive disorders, anxiety disorders, or both? Chest 2006; 130: 1039–1047.
44. Moy ML, Lantin ML, Harver A, Schwartzstein RM. Language of dyspnea in assessment of patients with acute asthma treated with nebulized albuterol. Am J Respir Crit Care Med 1998; 158: 749–753.
45. von Leupoldt A, Sommer T, Kegat S, Baumann HJ, Klose H, Dahme B et al. The unpleasantness of perceived dyspnea is processed in the anterior insula and amygdala. Am J Respir Crit Care Med 2008; 177: 1026–1032.
46. Rosenkranz MA, Busse WW, Sheridan JF, Crisafi GM, Davidson RJ. Are there neurophenotypes for asthma? Functional brain imaging of the interaction between emotion and inflammation in asthma. PLoS One 2012; 7: e40921.
47. Bender BG. Risk taking, depression, adherence, and symptom control in adolescents and young adults with asthma. Am J Respir Crit Care Med 2006; 173: 953–957.
48. Thomas M, McKinley RK, Freeman E, Foy C. Prevalence of dysfunctional breathing in patients treated for asthma in primary care: cross sectional survey. BMJ 2001; 322: 1098–1100.
49. Thomas M, McKinley RK, Mellor S, Watkins G, Holloway E, Scullion J et al. Breathing exercises for asthma: a randomised controlled trial. Thorax 2009; 64: 55–61.
50. Smith JR, Noble MJ, Musgrave S, Murdoch J, Price GM, Barton GR et al. The at-risk registers in severe asthma (ARRISA) study: a cluster-randomised controlled trial examining effectiveness and costs in primary care. Thorax 2012; 67: 1052–1056.
51. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360: 1715–1721.
52. Szefler SJ, Martin RJ. Lessons learned from variation in response to therapy in clinical trials. J Allergy Clin Immunol 2010; 125: 285–292.
53. Holgate ST. Stratified approaches to the treatment of asthma. Br J Clin Pharmacol 2013; 76: 277–291.